MBX · MBX Biosciences, Inc. · Executive Compensation
$53.12
-2.82 (-5.04%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q2 2025 earnings call transcript
Market Cap
$2.64B
Shares
49.66M
Volume · Nov 16
391.31K
Avg daily vol (3M)
525.58K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| P. Kent Hawryluk | President and Chief Executive Officer | $2,990,867 |
| Richard Bartram | Former Chief Financial Officer | $1,496,275 |
| Salomon Azoulay | Chief Medical Officer | $1,474,978 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Salomon Azoulay | Chief Medical Officer | $3,095,920 |
| P. Kent Hawryluk | President and Chief Executive Officer | $2,235,317 |
| Richard Bartram | Chief Financial Officer | $1,153,568 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| P. Kent Hawryluk | President and Chief Executive Officer | $4,862,064 |
| Richard Bartram | Chief Financial Officer | $1,051,106 |
| Salomon Azoulay | Chief Medical Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Peter Radovich | director | Appointed | 2026-10-22 |
| Steven Hoerter | President and Chief Executive Officer and principal executive officer | Appointed | 2026-07-13 |
| John Smither | Chief Financial Officer and principal financial officer | Appointed | 2026-07-13 |
| Edward T. Mathers | Class II director | Appointed | 2026-06-05 |
| Patrick J. Heron | Class II director | Appointed | 2026-06-05 |
| John Smither | Chief Financial Officer, on an interim and part-time basis | Appointed | 2026-02-27 |
| John Smither | Interim Chief Financial Officer | Appointed | 2026-02-27 |
|
Richard Bartram
“Mr. Bartram’s departure is not due to a dispute or disagreement with the Company or the Company’s auditors.”
|
Chief Financial Officer | Resigned | 2026-02-27 |
| Laurie Stelzer | chairperson of the Audit Committee of the Board | Appointed | 2026-01-22 |
| Laurie Stelzer | director | Appointed | 2026-01-22 |
| Steven Hoerter | executive chairperson of the Board | Appointed | 2025-11-06 |
| James M. Cornelius | member of the Company's board of directors | Resigned | 2025-11-06 |
| Tiba Aynechi, Ph.D. | Class I director | Appointed | 2025-06-06 |
| P. Kent Hawryluk | Class I director | Appointed | 2025-06-06 |
| Steven L. Hoerter | director | Appointed | 2025-04-07 |
Leadership
- Steven Hoerter CEO, Chairman
- John Smither CFO
- Ed Mathers Board Member
- Edward T. Mathers Board Member
- Laurie Stelzer Board Member
- Ora Pescovitz Board Member
- P. Kent Hawryluk Board Member
- Patrick J. Heron Board Member
- Peter Radovich Board Member
- Steven Ryder Board Member
- Tiba Aynechi Board Member
- Tiba Aynechi, Ph.D. Board Member
Key facts
CIK
1776111
CUSIP
55287L101
13F (30d)
150 filings
145 filers
Visit website
Investor relations